The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in DME Published in peer-reviewed journal Translational ...

SolidddVision smart glasses aim to restore vision for people living with macular degeneration, a condition that affects ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Essex Bio-Technology ( (HK:1061) ) has provided an announcement.

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

CU-06 is under clinical development by Curacle and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I drugs for Ulcerative Colitis have an 82% phase transition success rate ...

Fintel reports that on January 7, 2025, Citigroup initiated coverage of EyePoint Pharmaceuticals (NasdaqGM:EYPT) with a Buy ...

Opyl has entered a joint venture with X Firm to market its TrialKey platform in key markets, while Dimerix has inked another ...

Global Bispecific Antibodies Market Size 2024: > USD 8.5 Billion Approved Bispecific Antibodies Yearly and Quarterly Sales ...

ABI-110 is under clinical development by Avirmax and currently in Phase II for Polypoidal Choroidal Vasculopathy.

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...